Under this structure, which is common among alternative asset managers, Royalty Pharma owns its unique industry-leading ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $594 million. Its GAAP profit of $0.57 per share ...

Royalty Pharma intends to repurchase $2.0 billion of its shares in 2025 ... in adult growth hormone deficiency for Skytrofa. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, ...

Royalty Pharma intends to repurchase $2.0 billion of ... The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. aficamten In December 2024, Cytokinetics announced that ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

Royalty Pharma reports strong Q4 and FY 2024 financial growth, with projected 2025 Portfolio Receipts between $2.9 and $3.05 billion. Royalty Pharma plc reported strong financial results for Q4 ...